Clinical trials: Pregnancy, High Risk
Acute Kidney Injury
Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury
This is a Phase 2, dose-ranging, double-blind, double-dummy, placebo-controlled, randomized study preceded by an open label safety run-in, in patients at high risk for Cardiac Surgery Associated - Acute Kidney Injury (CSA-AKI)…
- Trial name
- CSA-AKI (NCT07625553)
- Testing
- R2R01
- Where
- Italy
- Volunteers
- 430 people
- Sponsor
- River 2 Renal Corp.
Carcinoma, Pancreatic Ductal, Mesothelioma
Amatuximab for High Mesothelin Cancers
Background: Amatuximab is a cancer treatment drug that targets mesothelin. High levels of this substance are found on some kinds of tumor cells.
- Conditions
- Carcinoma, Pancreatic Ductal, Mesothelioma, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01413451
- Testing
- Amatuximab (MORab-009)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Non-muscle Invasive Bladder Cancer
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
To determine the efficacy of oral APL-1202 administered consecutively for 12 weeks in subjects with high-risk NMIBC relapsed from intravesical chemo/BCG therapy based on the recurrence-free rate (RFR) at 12 months after APL-1202…
- Trial name
- NCT04498702
- Testing
- APL-1202 treatment
- Volunteers
- 41 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
- Trial name
- NCT03586661
- Testing
- Copanlisib, Niraparib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Diabetic Nephropathy
Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II.
- Trial name
- NCT00004266
- Testing
- Lisinopril, Nifedipine, Simvastatin
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01118351
- Testing
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
HSIL, High Grade Squamous Intraepithelial Lesion, DNA Methylation
Predictive Biomarkers for Precision Management of Pre-cancerous Cervical Neoplasia
The goal of this observational study (retrospective cohort study) is to determine whether DNA methylation status in archived cervical cytology samples can predict regression, persistence, or progression of high-grade cervical…
- Conditions
- HSIL, High Grade Squamous Intraepithelial Lesion, DNA Methylation, CIN - Cervical Intraepithelial Neoplasia
- Trial name
- NCT07895641
- Testing
- DNA methylation
- Where
- Sweden
- Volunteers
- 199 people
- Sponsor
- Lund University
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to NCT00362297. On 28 April 2011, the two records were split for administrative purposes and each trial was given its own unique study record.
- Trial name
- NCT01346475
- Testing
- valacyclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
End Stage Renal Disease (ESRD)
Comparison of the Removal of Uremic Toxins With Medium Cut-off and Super High-flux Vitamin E-coated Dialyzers
End-stage renal disease (ESRD) induces an accumulation of uremic toxins responsible for increased morbidity and mortality. These toxins cover a wide range of molecules, classified according to their molecular weight as small-size…
- Trial name
- E-FLUX (NCT05610683)
- Testing
- Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Poitiers University Hospital
Ovary Cancer
Mesenteric Infiltration in Ovarian Cancer
To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an…
- Trial name
- MIO (NCT06331130)
- Testing
- Computed Tomography
- Where
- Italy
- Volunteers
- 510 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all…
- Trial name
- NCT06365853
- Testing
- Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops
- Where
- 41 sites in United States, Australia and 5 more
- Volunteers
- 108 people
- Sponsor
- AbbVie
Chronic Kidney Diseases, Renal Disease
Evaluation of Renastep
Evaluation of Renastep is a 28-day long, prospective nutritional study that will recruit 15 patients aged between 3 and 18 years of age with Chronic Kidney Disease.
- Trial name
- Renastep (NCT03602937)
- Testing
- Renastep
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Vitaflo International, Ltd
Clear Cell Renal Cell Carcinoma
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients.
- Trial name
- HARRIER (NCT07084909)
- Testing
- piflufolastat F 18
- Where
- 2 sites in United States
- Sponsor
- Lantheus Medical Imaging
Ovarian Cancer, Fallopian Tube Cancers
Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
The goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum changes the tumor immune environment.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- NCT07815704
- Testing
- Standard of Care + atorvastatin, Standard of Care (SOC)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Ovarian Hyperstimulation Syndrome
The Use of GnRH Agonist Trigger in the Prevention of OHSS
To compare the incidence of ovarian hyperstimulation syndrome (OHSS) and implantation rate between high responder patients using Gonadotropin releasing GnRH) agonist or human chorionic gonadotropin (hCG) to trigger final oocyte…
- Trial name
- NCT00349258
- Testing
- Leuprolide acetate
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Urinary Bladder Neoplasms
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor…
- Trial name
- NCT04172675
- Testing
- Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C)
- Where
- 150 sites in United States, Argentina and 15 more
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumors, High Grade Gliomas
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET…
- Conditions
- Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer
- Trial name
- NCT00918281
- Testing
- Fluciclatide Injection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- GE Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.